



Ophthalmic
Therapeutic
Innovation

Plug & Play Venture Pitch (Virtual)

Redefine Glaucoma Patient Care by Intraocular Pressure (IOP) Normalization

~ OTI-2024 – A First-in-Class Curative Therapy ~

Tina Guanting Qiu, MD PhD, EMBA

CEO/Founder/Board

Ophthalmic Therapeutic Innovation, Inc.

Email: qiu-tina@ophthalmic-innovation.com

Mobile: 857 400 4607

Website: <http://ophthalmic-innovation.com>

Pitching Date: Friday, July 17th 2026

Company Confidential Not for Distribution



Problem



- No. 1 leading cause of irreversible blindness;
- 118 million patients worldwide by 2040,
- 1/3 patients become **legally blind**,
- Current there is no cure.


Glaucoma is treated—but not repaired.

- Current eye drops, surgery, laser
- ✓ Lower eye pressure –**symptom relief**.
- ✗ Do not repair damaged pressure sensor and sensing cells.

Results

- lifelong daily drops –**poor compliance**
 - **Poor responders**
 - Progression to **surgery** (unstoppable)
 - irreversible **blindness**.

Value Proposition




- Unlike current standard care of IOP lowering as symptom relief, required a strict dosing compliance.
- OTI-2024 is the first pathway-based **tissue rejuvenation** therapy, designed to **repair** pressure sensor functionality and **normalize** IOP irregularities,
- Treating poor responders and enabling a **disease free** IOP **drug holiday** with dosing flexibility.

Faster, Cheaper and Better to Market.

Our Solution: OTI-2024 – a Drug Holiday Inducer

OTI-2024 Target Site: BM and Sensing Cells



OTI-2024 (Trabodenoson): adenosine A1 receptor agonist (small molecule)

Repairs

Pressure sensor damage (sensing cell loss)



Normalizes

IOP Irregularities (random spikes)



Enables

Potential **drug holiday & dosing flexibility.**

Dual Revenue Strategy

OTI is creating a new MMP therapeutic market for glaucoma in decades to come.

Near-term

Strategic Licensing

- Regional licenses
- Global partnerships
- Upfront payments
- Milestones
- Royalties


Long-term

Commercial Product (eye drops)

- Prescription ophthalmic therapy
- US/EU Global commercialization
- Lifecycle expansion
- Sustained release products
- SiRNA genetic products

\$8.0B Global Drug Market in 2023
\$11.5B Global Drug Market by 2030

GLAUCOMA MARKET SHARES IN 2030
PROJECTION



Multiple exit opportunities: licensing, acquisition, IPO

Competitive Advantage

OTI-2024 /MMP Therapeutics

- **First-in-class** positioning, potential **curative therapy**.
- Potential **first line therapy** in replacing prostaglandin glaucoma market dominance (**60% shares**) in the past 30 years.
- Completed MMP Target Validation in Glaucoma Patients –**Derisked, anticipated Ph3 success**
- Existing Phase 2 clinical efficacy and safety.
- FDA **505(b)(2)** pathway
- Novel IP Portfolio (**20–year market exclusivity**)
- Extremely **high capital efficiency** (\$250K raised in total).

Current Status

OTI LLC formed in Massachusetts on November 2023, converted to DE C Corp on March 2026.

Clinical

800+ patients previously exposed

Phase 2 efficacy: MMP benefits

Excellent safety

FDA

New IND Application submitted (pending)

FDA Type C Completed

FDA Type D Completed

505(b)(2) Pathway

Phase 3/ 6-month Pivotal Trial aligned

Patents

- 2 PCTs/Multiple provisionals
- Global Filing Completed (6-7 jurisdictions)
- 100% OTI ownership


Financing

- 250K raised from surgeon investors.
- Raising \$250K bridge/\$5M Seed Round.
- Extremely high capital efficiency.
- Estimated total \$40MM, 3-4 years to bring OTI-2024 to market with **high** success.

Next Milestone: reformulation & IND clearance → Phase 3 initiation

Total: ~ \$40MM, 3-4 years to FDA approval.

Our Ask: \$5.0MM Seed Financing



- 03. 2026 Perfuse Therapeutic- Bayer deal: \$2.45B (\$300M upfront), Ph2 glaucoma neural protection asset
- 05.2024: Eyebio –Merck: deal: \$1.3B upfront, up to \$1.7 billion future milestone. Ph2 asset treats wet AMD poor responders.

Our Team & Advisors

Board Directors



Tina Guanting Qiu,
MD/PhD, EMBA
CEO, Board Director




Ryan Bleeks, MS
Independent Board
Director

Scientific Medical Advisors



**James C Tsai, MD, MBA, Scientific
Medical Advisory Board,** President of
the New York Eye and Ear Infirmary of
Mount Sinai (NYEE)



**Louis B. Cantor, MD: Scientific
Medical Advisory Board (SAB)**
Jay C. & Lucile L. Kahn Professor
Emeritus of Glaucoma Research and
Education, **Indiana University.**



Meenakshi Chaturvedi,
MD, Director of
Glaucoma, Loyola
Medicine, Chicago, IL



Physicians/Surgeons -Angel Investors

Board Advisor



Catherine G Cohen
Strategic Advisor
Government Relation &
Policy (D.C)



Art Healey, JD/CPA
Finance Executive



**Saya Nagori, MD, Investor,
Board Advisor.**
Glaucoma Surgeon @ Vision MD,
DC Area. CMO @ Eyefacts, Inc.



**Aman Shukairy, MD,
Investor & Clinical SAB.**
Glaucoma Surgeon @
Premier Glaucoms & Eye
Care, MI.



Michael Banks, MD
Angel Investor, Board Observer



Thank You Very Much!

Use of Proceeds (\$5M Seed) and Summary


Capital Directly Enables Reformulation & IND Clearance

Use of Funds

- GMP grade API manufacturing
- Eye drops reformulation (Optimization with New Composition Matter)
- Bioequivalence study & 6-month Ocular Tox Study
- CMC development and stability studies
- IND amendment and clearance

Outcome


- IND-cleared at eCTD channel
- Fully enabled Phase 3 clinical trial
- Major valuation step-up




\$5M financing converts FDA alignment into a Phase 3-enabled asset.

Phase 2 Clinical Efficacy: Trabodenoson/MMP on **IOP Normalization** towards Drug Holiday

A: Phase 2 Trabodenoson Dose Escalation in early stage POAG/OH.



B: Phase 2 Trabodenoson in Latanoprost **Poor Responders**- improved LAT performance.



MMP on Pressure sensor rejuvenation results in:

1. Signature IOP Improvement profile
2. Dosing switch –precursor of drug holiday
3. Effective in Latanoprost poor responders
4. MMP treatment steady state – IOP Plateau (drug holiday).

OTI's Solution and Competitive Landscape

